Cochrane · systematic review · CD002827
Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Lunn, MPT, Nobile‐Orazio, E · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy
Population: people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants improved in disability Rituximab vs placebo | RR 3.51 [1.3, 9.45] | 2 studies · 73 participants | Low Downgraded: imprecision |
Mean improvement in disability Rituximab vs placebo | no estimate extracted | 2 studies · 73 participants | Low Downgraded: imprecision |
Improvement in 10‐metre walk time at 8 to 12 months1 Rituximab vs placebo | no estimate extracted | 2 studies · 68 participants | Moderate Downgraded: imprecision |
Participant subjective impression of change stable or improved at 8 to 12 months Rituximab vs placebo | RR 1.86 [1.27, 2.71] | 2 studies · 70 participants | Low Downgraded: imprecision, indirectness |
Change in serum IgM paraprotein concentration 8 months after treatment1 Rituximab vs placebo | no estimate extracted | 1 study · 26 participants | Moderate Downgraded: imprecision |
Any adverse event Rituximab vs placebo | RR 1.18 [0.84, 1.66] | 2 studies · 80 participants | Very low Downgraded: imprecision, inconsistency |
Rituximab compared to placebo for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Population: patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants improved on disability score at 6 months INCAT leg disability score Rituximab vs placebo | RR 9 [0.53, 151.94] | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Mean improvement in disability score at 6 months Rituximab vs placebo | no estimate extracted | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Improvement in 10‐metre walk time at 6 months Rituximab vs placebo | no estimate extracted | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Patient subjective impression of change at 6 months ‐ number of patients reporting improvement Rituximab vs placebo | RR 15 [0.94, 238.23] | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Change in IgM level 8 months after treatment Rituximab vs placebo | no estimate extracted | 1 study · 26 participants | Low Downgraded: risk of bias |
Any adverse Event Rituximab vs placebo | RR 1.33 [0.9, 1.98] | 1 study · 26 participants | Very low Downgraded: risk of bias |